Trial finds HydroEye (SBH) benefits Dry Eye Disease

Results from the HydroEye clinical trial of HydroEye (DHA, EPA and GLA), from ScienceBased Health, showed that the omega fatty acid supplement relieved the symptoms of Dry Eye Disease. The study, a multicenter, double-blind, randomized, placebo-controlled clinical trial of 38 post-menopausal women with tear dysfunction in both eyes, found that HydroEye, compared to a placebo, provided significant benefits related to Dry Eye Disease symptoms. The findings were based on symptoms measured using the OSDI questionnaire and on measurements of dry eye through the expression of 2 inflammatory markers measured by conjunctival impression cytologies plus corneal smoothness.

Within three months, the group treated with HydroEye showed statistically significant improvements in irritation symptoms of dry eye, and no progression of ocular surface inflammation or corneal irregularity. The placebo group's dry eye symptoms showed no improvement over the six-month testing period. The study was published in Cornea: "Long-term Supplementation With n-6 and n-3 PUFAs Improves Moderate-to-Severe Keratoconjunctivitis Sicca: A Randomized Double-Blind Clinical Trial" Sheppard, John et al. Cornea July 2013 doi: 10.1097/ICO.0b013e318299549c